Interview with Leigh Berryman , Chief Executive Officer, Maccine
Which previous professional experiences have led you to join Maccine? Getting my own company to go public in 2006 in Canada was a success for me; the company had grown…
Address: 10 Science Park Road 01-05 The Alpha Singapore Science Park II Singapore 117684,Singapore
Tel: +65 6622 9540
Web: http://www.maccine.com/index.php
Maccine is an established preclinical contract research organization providing innovative discovery support and regulatory safety assessment services.
Operating on a collaborative partnering model, Maccine has developed a portfolio of in vivo assays in key therapeutic areas including Neurology, Psychiatry, Metabolic Disorders, Pain & Inflammation, Oncology, Musculoskeletal Disorders and Women’s Health.
Naturalistic models, clinical biomarkers and clinical technology platforms are employed to better represent the clinical disease state. The team is supported by significant investment in high-end technology and access to a world class scientific community.
Preclinical Contract Research
Which previous professional experiences have led you to join Maccine? Getting my own company to go public in 2006 in Canada was a success for me; the company had grown…
Kevin Zou highlights Novartis Oncology’s footprint and priorities in the diverse Asia-Pacific region, the challenges of introducing cutting-edge cell and gene therapies, how the company works with regulators and payers…
Medtech industry veteran Sanjay Prabhakaran outlines the footprint and strategy of women’s health specialist Hologic in the dynamic Asia-Pacific region, how it leveraged its molecular diagnostics expertise to pivot towards…
Novo Nordisk Singapore’s Praful Chakkarwar explains how he leverages his experience in a range of geographies in his current role, how COVID-19 has helped facilitate the affiliate’s digital transformation, the…
Nawal Roy of global digital health platform Holmusk which aims to establish data as a core utility to the treatment of behavioural health disorders explains the challenges of working in…
ASLAN Pharmaceuticals is a clinical-stage immunology-focused biopharmaceutical company. CEO Dr Carl Firth reveals why the company has shifted its focus from oncology to autoimmune diseases. He explains why their lead…
As the most important pharma hub in its region, and one of the most important globally, many companies look to launch new products in Singapore first before expanding to other…
Dr Choong May Ling, Mimi, CEO of Singapore’s Health Sciences Authority (HSA), one of the leading regulatory bodies in the Asia-Pacific region, outlines the impact of Singapore’s status as a…
At USD 150 billion, Asia-Pacific is home to the world’s second largest medtech market and, with a CAGR of nine percent, certainly its most dynamic. Chronic underfunding of healthcare systems…
Lance Little, managing director for Roche Diagnostics in Asia Pacific and board member of the Asia Pacific Medical Technology Association (APACMed), shares how COVID has affected their business in the…
MSD’s Ashish Pal describes how he led the Singapore, Malaysia, and Brunei cluster through a challenging 2020; the importance of leveraging learnings from the past year to create a more…
In an exclusive and wide-ranging interview, Harjit Gill outlines the work of pan-Asia-Pacific medtech association APACMed, how COVID-19 represents a chance to change the global narrative on medtech in healthcare,…
Dr Gideon Ho, co-founder and CEO of HistoIndex, shares the story of the company’s establishment in 2010, their proprietary technology to provide the world’s first stain-free AI-driven biopsy and tissue…
See our Cookie Privacy Policy Here
